FMP
Enanta Pharmaceuticals, Inc.
ENTA
NASDAQ
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
6.65 USD
-0.18 (-2.71%)
Retained Earning Schedule
Year
2024
2023
2022
2021
Retained Earnings (Previous Year)
-207M
-73.18M
48.58M
127.57M
Net Income
-116.05M
-133.82M
-121.75M
-79M
Stock Repurchases
0
0
-1.23M
-534k
Dividend Paid
0
0
0
0
Retained Earnings
-323.04M
-207M
-73.18M
48.58M
Other Distributions
-116.05M
-133.82M
-122.98M
-79.53M
All figures are in USD.
